Theriva Biologics Inc. (TOVX) - Total Assets
Based on the latest financial reports, Theriva Biologics Inc. (TOVX) holds total assets worth $38.25 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore TOVX cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Theriva Biologics Inc. - Total Assets Trend (1993–2025)
This chart illustrates how Theriva Biologics Inc.'s total assets have evolved over time, based on quarterly financial data. See Theriva Biologics Inc. shareholders equity for net asset value and shareholders' equity analysis.
Theriva Biologics Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Theriva Biologics Inc.'s total assets of $38.25 Million consist of 45.7% current assets and 54.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.1% |
| Accounts Receivable | $3.83 Million | 10.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $19.62 Million | 51.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1993–2025)
This chart illustrates how Theriva Biologics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Theriva Biologics Inc. worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Theriva Biologics Inc.'s current assets represent 45.7% of total assets in 2025, a decrease from 94.4% in 1993.
- Cash Position: Cash and equivalents constituted 34.1% of total assets in 2025, down from 94.4% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 0.0% in 1993.
- Asset Diversification: The largest asset category is intangible assets at 51.3% of total assets.
Theriva Biologics Inc. Competitors by Total Assets
Key competitors of Theriva Biologics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Genfit S.A.
PA:GNFT
|
France | €157.93 Million |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
Altimmune Inc
NASDAQ:ALT
|
USA | $279.93 Million |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
China | CN¥1.48 Billion |
Theriva Biologics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.63 | 1.53 | 36.05 |
| Quick Ratio | 1.63 | 1.53 | 36.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.49 Million | $4.33 Million | $73.53 Million |
Theriva Biologics Inc. - Advanced Valuation Insights
This section examines the relationship between Theriva Biologics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.14 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 8.2% |
| Total Assets | $38.24 Million |
| Market Capitalization | $10.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values Theriva Biologics Inc.'s assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Theriva Biologics Inc.'s assets grew by 8.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Theriva Biologics Inc. (1993–2025)
The table below shows the annual total assets of Theriva Biologics Inc. from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $38.24 Million | +8.17% |
| 2024-12-31 | $35.35 Million | -35.98% |
| 2023-12-31 | $55.22 Million | -23.16% |
| 2022-12-31 | $71.86 Million | +2.13% |
| 2021-12-31 | $70.36 Million | +736.68% |
| 2020-12-31 | $8.41 Million | -51.20% |
| 2019-12-31 | $17.23 Million | -42.82% |
| 2018-12-31 | $30.14 Million | +60.00% |
| 2017-12-31 | $18.84 Million | -16.27% |
| 2016-12-31 | $22.50 Million | -27.06% |
| 2015-12-31 | $30.84 Million | +61.12% |
| 2014-12-31 | $19.14 Million | +17.76% |
| 2013-12-31 | $16.26 Million | +21.11% |
| 2012-12-31 | $13.42 Million | +79.55% |
| 2011-12-31 | $7.48 Million | +81.85% |
| 2010-12-31 | $4.11 Million | +0.87% |
| 2009-12-31 | $4.08 Million | -44.81% |
| 2008-12-31 | $7.39 Million | -45.83% |
| 2007-12-31 | $13.63 Million | +8.93% |
| 2006-12-31 | $12.52 Million | +769.17% |
| 2005-12-31 | $1.44 Million | -4.93% |
| 2002-12-31 | $1.51 Million | -26.34% |
| 2001-12-31 | $2.06 Million | -62.27% |
| 2000-12-31 | $5.45 Million | +7.96% |
| 1999-12-31 | $5.05 Million | +74.09% |
| 1998-12-31 | $2.90 Million | +314.29% |
| 1997-12-31 | $700.00K | -75.00% |
| 1996-12-31 | $2.80 Million | +27.27% |
| 1995-12-31 | $2.20 Million | +450.00% |
| 1994-12-31 | $400.00K | -77.78% |
| 1993-12-31 | $1.80 Million | -- |
About Theriva Biologics Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcin… Read more